What were Pfizer's Q1 2025 results?

Pfizer reported higher revenue driven by newer drugs, but specific figures have not been disclosed yet.

How did new drugs impact Pfizer's revenue?

New drugs were the primary driver of revenue growth in Q1, reflecting the company's shift away from COVID-19 products.

Did Pfizer provide future guidance?

Pfizer has not issued specific guidance yet, but it reiterated its focus on innovation.

How did Pfizer's stock react to the results?

The stock showed little movement as investors await more details.

Pfizer Q1 2025: New Drugs Drive Revenue Growth

Pfizer's first-quarter 2025 results revealed that newer drugs are now the primary growth driver, as the company continues to pivot away from its COVID-19 product line.

Pfizer (NYSE: PFE) reported its first-quarter 2025 financial results, highlighting a clear shift in revenue composition toward newer medicines. According to a report obtained by TheStreet, the company's revenue increased year-over-year, driven by recently launched products.

Key Financial Results

Metric	Q1 2025	Q1 2024	Change
Revenue	Not disclosed	Not disclosed	-
Net Income	Not disclosed	Not disclosed	-
EPS	Not disclosed	Not disclosed	-

Note: Specific figures were not provided in the initial report.

Key Highlights

Pfizer stated that newer drugs significantly contributed to revenue growth, reflecting the success of its strategy to diversify its portfolio and reduce reliance on COVID-19 products. While specific drug names were not mentioned, they are expected to include oncology and rare disease treatments.

Guidance

Pfizer has not yet issued specific guidance for fiscal 2025, but it emphasized continued focus on innovation and pipeline expansion.

Stock Impact

Pfizer's stock (PFE) showed little movement following the announcement, as investors await more detailed financials and forward guidance.

What This Means for Investors

The results indicate that Pfizer is making progress in building a sustainable product portfolio after the decline in COVID-19 vaccine sales. However, it remains crucial to monitor the performance of new drugs and their ability to offset the pandemic-related revenue drop.